Telehealth startup Genome Medical recently raised $60 million in funding led by Casdin Capital. It’s using part of the funds to acquire GeneMatters, which would add more genetic counselors to its staff.
The Boston-based company plans to develop small-molecule therapeutics that go after historically "undruggable" targets using a process known as protein degradation.
Transitioning to PDPM models significantly shifted the healthcare industry. By replacing the RUG system, healthcare providers cut waste and more accurately reflect the care each patient received.
The partnership includes a $30 million upfront payment from Bayer and potentially more than $100 million in milestones per program generated through the partnering of the German drugmaker's molecule library and Recursion's artificial intelligence-based drug discovery platform.
The study design is still being finalized, and the company is thus not yet divulging too many details. However, CEO David Daly said it would be significantly larger than the previous DETECT-A, multi-center and would include both men and women.
The company said it plans to expand into new supply chains for advanced therapeutics in addition to cell and gene therapies, as well as expanding its footprint in Europe and the Asia-Pacific region.
The startup, founded by a prominent health policy expert and a biotech industry executive, aims to bring down the cost of drugs by re-engineering and making less costly the process by which they are discovered and brought to patients.
Patient expectations continue to evolve, and healthcare practices that fail to adapt risk more than just revenue—they risk losing trust.
The company is targeting pathways such as SHP2 and KRAS G12C. RAS mutations have been an attractive target in oncology due to the central role they play in cancers.
The company has a 10,000-patient prospective trial with Geisinger fully enrolled to test CancerSEEK, a test developed at Johns Hopkins University.
Third Rock and ARCH led the launch of the company, which will look at ways to target genetic modifiers that can protect against certain diseases.
The round, led by SoftBank Vision Fund, is more than six times the size of Relay's Series B round, which it closed in December 2017.
A new report from Relatient, A Data-Driven Guide to Patient Access Succes, highlights how focusing on data accuracy and relevance can enhance the performance of healthcare practices.
Estimates of the incidence of FSHD, which has two types, range from 1-in-20,000 to 1-in-8,333, or about 870,000 cases worldwide.